Magnetic resonance imaging of hepatocellular carcinoma using contrast media

Oncology

Volumn 75, Issue SUPPL. 1, 2008, Pages 72-82

  Kim, Myeong Jin ^a   Choi, Jin Young ^a   Chung, Yong Eun ^a   Choi, Sun Young ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

Hepatocellular carcinoma; Magnetic resonance contrast media; Magnetic resonance imaging

Indexed keywords

FERUCARBOTRAN; GADOBENATE DIMEGLUMINE; GADOBENIC ACID; GADOLINIUM CHELATE; GADOXETIC ACID; MANGAFODIPIR; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT; SUPERPARAMAGNETIC IRON OXIDE;

CANCER DIAGNOSIS; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; DIFFUSION WEIGHTED IMAGING; DRUG UPTAKE; ECHOGRAPHY; EXTRACELLULAR FLUID; HUMAN; INTERMETHOD COMPARISON; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; METASTASIS; MULTIDETECTOR COMPUTED TOMOGRAPHY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SENSITIVITY AND SPECIFICITY; SPIRAL COMPUTER ASSISTED TOMOGRAPHY; TUMOR DIFFERENTIATION; TUMOR VASCULARIZATION;

AGED; ANIMALS; CARCINOMA, HEPATOCELLULAR; CONTRAST MEDIA; DISEASE MODELS, ANIMAL; HUMANS; IRON; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; OXIDES; RATS;

EID: 58149097428     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000173427     Document Type: Conference Paper

References (126)

1. Willatt JM, Hussain HK, Adusumilli S, Marrero JA: MR imaging of hepatocellular carcinoma in the cirrhotic liver: challenges and controversies. Radiology 2008;247:311-330.
2. Ito K: Hepatocellular carcinoma: conventional MRI findings including gadoliniumenhanced dynamic imaging. Eur J Radiol 2006;58:186-199.
3. Taouli B, Losada M, Holland A, Krinsky G: Magnetic resonance imaging of hepatocellular carcinoma. Gastroenterology 2004;127:S144-S152.
4. Hanna RF, Aguirre DA, Kased N, Emery SC, Peterson MR, Sirlin CB: Cirrhosis-associated hepatocellular nodules: correlation of histopathologic and MR imaging features. Radiographics 2008;28:747-769.
5. Rode A, Bancel B, Douek P, et al:Small nodule detection in cirrhotic livers: evaluation with US, spiral CT, and MRI and correlation with pathologic examination of explanted liver. J Comput Assist Tomogr 2001;25:327-336.
6. Libbrecht L, Bielen D, Verslype C, et al: Focal lesions in cirrhotic explant livers: pathological evaluation and accuracy of pretransplantation imaging examinations. Liver Transpl 2002;8:749-761.
7. Colli A, Fraquelli M, Casazza G, et al: Accuracy of ultrasonography, spiral CT, magnetic resonance, and alpha-fetoprotein in diagnosing hepatocellular carcinoma: a systematic review. Am J Gastroenterol 2006;101:513-523.
8. van den Bos IC, Hussain SM, Terkivatan T, Zondervan PE, de Man RA: Stepwise carcinogenesis of hepatocellular carcinoma in the cirrhotic liver: demonstration on serial MR imaging. J Magn Reson Imaging 2006;24:1071-1080.
9. Choi D, Mitchell DG, Verma SK, et al: Hepatocellular carcinoma with indeterminate or false-negative findings at initial MR imaging: effect on eligibility for curative treatment initial observations. Radiology 2007;244:776-783.
10. Shah TU, Semelka RC, Pamuklar E, et al: The risk of hepatocellular carcinoma in cirrhotic patients with small liver nodules on MRI. Am J Gastroenterol 2006;101:533-540.
11. Mitchell DG, Palazzo J, Hann HW, Rifkin MD, Burk DL Jr, Rubin R: Hepatocellular tumors with high signal on T1-weighted MR images: chemical shift MR imaging and histologic correlation. J Comput Assist Tomogr 1991;15:762-769.
12. Kreft BP, Tanimoto A, Baba Y, et al: Diagnosis of fatty liver with MR imaging. J Magn Reson Imaging 1992;2:463-471.
13. Martin J, Sentis M, Zidan A, et al: Fatty metamorphosis of hepatocellular carcinoma: detection with chemical shift gradient-echo MR imaging. Radiology 1995;195:125-130.
14. Shimizu A, Ito K, Sasaki K, et al: Small hyperintense hepatic lesions on T1-weighted images in patients with cirrhosis: evaluation with serial MRI and imaging features for clinical benignity. Magn Reson Imaging 2007;25:1430-1436.
15. Ito K, Mitchell DG, Outwater EK, Szklaruk J, Sadek AG: Hepatic lesions: discrimination of nonsolid, benign lesions from solid, malignant lesions with heavily T2-weighted fast spin-echo MR imaging. Radiology 1997;204:729-737.
16. Jeong YY, Mitchell DG, Holland GA: Liver lesion conspicuity: T2-weighted breath-hold fast spin-echo MR imaging before and after gadolinium enhancement - initial experience. Radiology 2001;219:455-460.
17. Hecht EM, Holland AE, Israel GM, et al: Hepatocellular carcinoma in the cirrhotic liver: gadolinium-enhanced 3D T1-weighted MR imaging as a stand-alone sequence for diagnosis. Radiology 2006;239:438-447.
18. Yoshida H, Itai Y, Ohtomo K, Kokubo T, Minami M, Yashiro N: Small hepatocellular carcinoma and cavernous hemangioma: differentiation with dynamic FLASH MR imaging with Gd-DTPA. Radiology 1989;171:339-342.
19. Hamm B, Fischer E, Taupitz M: Differentiation of hepatic hemangiomas from metastases by dynamic contrast-enhanced MR imaging. J Comput Assist Tomogr 1990;14:205-216.
20. Ito K, Choji T, Nakada T, Nakanishi T, Kurokawa F, Okita K: Multislice dynamic MRI of hepatic tumors. J Comput Assist Tomogr 1993;17:390-396.
21. Peterson MS, Baron RL, Murakami T: Hepatic malignancies: usefulness of acquisition of multiple arterial and portal venous phase images at dynamic gadolinium-enhanced MR imaging. Radiology 1996;201:337-345.
22. Tsurusaki M, Semelka RC, Uotani K, Sugimoto K, Fujii M, Sugimura K: Prospective comparison of high- and low-spatial-resolution dynamic MR imaging with sensitivity encoding (SENSE) for hypervascular hepatocellular carcinoma. Eur Radiol 2008;18:2206-2212.
23. Mori K, Yoshioka H, Takahashi N, et al: Triple arterial phase dynamic MRI with sensitivity encoding for hypervascular hepatocellular carcinoma: comparison of the diagnostic accuracy among the early, middle, late, and whole triple arterial phase imaging. AJR Am J Roentgenol 2005;184:63-69.
24. Taouli B, Krinsky GA: Diagnostic imaging of hepatocellular carcinoma in patients with cirrhosis before liver transplantation. Liver Transpl 2006;12:S1-S7.
25. Lauenstein TC, Salman K, Morreira R, et al: Gadolinium-enhanced MRI for tumor surveillance before liver transplantation: center-based experience. AJR Am J Roentgenol 2007;189:663-670.
26. Krinsky GA, Lee VS, Theise ND, et al: Hepatocellular carcinoma and dysplastic nodules in patients with cirrhosis: prospective diagnosis with MR imaging and explantation correlation. Radiology 2001;219:445-454.
27. Burrel M, Llovet JM, Ayuso C, et al: MRI angiography is superior to helical CT for detection of HCC prior to liver transplantation: an explant correlation. Hepatology 2003;38:1034-1042.
28. Kudo M, Okanoue T: Management of hepatocellular carcinoma in Japan: consensus-based clinical practice manual proposed by the Japan Society of Hepatology. Oncology 2007;72(suppl 1):2-15.
29. Bruix J, Sherman M: Management of hepatocellular carcinoma. Hepatology 2005;42:1208-1236.
30. Kim SR, Ando K, Mita K, et al: Superiority of CT arterioportal angiography to contrast-enhanced CT and MRI in the diagnosis of hepatocellular carcinoma in nodules smaller than 2 cm. Oncology 2007;72(suppl 1):58-66.
31. Shinmura R, Matsui O, Kadoya M, et al: Detection of hypervascular malignant foci in borderline lesions of hepatocellular carcinoma: comparison of dynamic multi-detector row CT, dynamic MR imaging and superparamagnetic iron oxide-enhanced MR imaging. Eur Radiol 2008;18:1918-1924.
32. Kim YK, Lee YH, Kim CS, Han YM: Added diagnostic value of T2-weighted MR imaging to gadolinium-enhanced three-dimensional dynamic MR imaging for the detection of small hepatocellular carcinomas. Eur J Radiol 2008;67:304-310.
33. Earls JP, Theise ND, Weinreb JC, et al:Dysplastic nodules and hepatocellular carcinoma: thin-section MR imaging of explanted cirrhotic livers with pathologic correlation. Radiology 1996;201:207-214.
34. Li CS, Chen RC, Lii JM, et al: Magnetic resonance imaging appearance of well-differentiated hepatocellular carcinoma. J Comput Assist Tomogr 2006;30:597-603.
35. van den Bos IC, Hussain SM, Dwarkasing RS, et al: MR imaging of hepatocellular carcinoma: relationship between lesion size and imaging findings, including signal intensity and dynamic enhancement patterns. J Magn Reson Imaging 2007;26:1548-1555.
36. Kim T, Baron RL, Nalesnik MA: Infarcted regenerative nodules in cirrhosis: CT and MR imaging findings with pathologic correlation. AJR Am J Roentgenol 2000;175:1121-1125.
37. Yu JS, Kim KW, Jeong MG, Lee JT, Yoo HS: Nontumorous hepatic arterial-portal venous shunts: MR imaging findings. Radiology 2000;217:750-756.
38. Yu JS, Kim KW, Sung KB, Lee JT, Yoo HS: Small arterial-portal venous shunts: a cause of pseudolesions at hepatic imaging. Radiology 1997;203:737-742.
39. Jeong YY, Mitchell DG, Kamishima T: Small (< 20 mm) enhancing hepatic nodules seen on arterial phase MR imaging of the cirrhotic liver: clinical implications. AJR Am J Roentgenol 2002;178:1327-1334.
40. Shimizu A, Ito K, Koike S, Fujita T, Shimizu K, Matsunaga N: Cirrhosis or chronic hepatitis: evaluation of small (≤ 2-cm) early-enhancing hepatic lesions with serial contrast-enhanced dynamic MR imaging. Radiology 2003;226:550-555.
41. Holland AE, Hecht EM, Hahn WY, et al: Importance of small (≤ 20-mm) enhancing lesions seen only during the hepatic arterial phase at MR imaging of the cirrhotic liver: evaluation and comparison with whole explanted liver. Radiology 2005;237:938-944.
42. Byrnes V, Shi H, Kiryu S, Rofsky NM, Afdhal NH: The clinical outcome of small (< 20 mm) arterially enhancing nodules on MRI in the cirrhotic liver. Am J Gastroenterol 2007;102:1654-1659.
43. Ito K, Fujita T, Shimizu A, et al: Multiarterial phase dynamic MRI of small early enhancing hepatic lesions in cirrhosis or chronic hepatitis: differentiating between hypervascular hepatocellular carcinomas and pseudolesions. AJR Am J Roentgenol 2004;183:699-705.
44. Hong HS, Kim HS, Kim MJ, De Becker J, Mitchell DG, Kanematsu M: Single breathhold multiarterial dynamic MRI of the liver at 3T using a 3D fat-suppressed keyhole technique. J Magn Reson Imaging 2008;28:396-402.
45. Hayashida M, Ito K, Fujita T, et al: Small hepatocellular carcinomas in cirrhosis: differences in contrast enhancement effects between helical CT and MR imaging during multiphasic dynamic imaging. Magn Reson Imaging 2008;26:65-71.
46. Yu JS, Lee JH, Chung JJ, Kim JH, Kim KW: Small hypervascular hepatocellular carcinoma: limited value of portal and delayed phases on dynamic magnetic resonance imaging. Acta Radiol 2008;49:735-743.
47. Reimer P, Tombach B: Hepatic MRI with SPIO: detection and characterization of focal liver lesions. Eur Radiol 1998;8:1198-1204.
48. Tanimoto A, Kuribayashi S: Application of superparamagnetic iron oxide to imaging of hepatocellular carcinoma. Eur J Radiol 2006;58:200-216.
49. Semelka RC, Helmberger TK: Contrast agents for MR imaging of the liver. Radiology 2001;218:27-38.
50. Tanimoto A, Wakabayashi G, Shinmoto H, Nakatsuka S, Okuda S, Kuribayashi S: Superparamagnetic iron oxide-enhanced MR imaging for focal hepatic lesions: a comparison with CT during arterioportography plus CT during hepatic arteriography. J Gastroenterol 2005;40:371-380.
51. Seneterre E, Taourel P, Bouvier Y, et al: Detection of hepatic metastases: ferumoxides-enhanced MR imaging versus unenhanced MR imaging and CT during arterial portography. Radiology 1996;200:785-792.
52. Hori M, Murakami T, Kim T, et al: Detection of hypervascular hepatocellular carcinoma: comparison of SPIO-enhanced MRI with dynamic helical CT. J Comput Assist Tomogr 2002;26:701-710.
53. Lee JM, Kim IH, Kwak HS, Youk JH, Han YM, Kim CS: Detection of small hypervascular hepatocellular carcinomas in cirrhotic patients: comparison of superparamagnetic iron oxide-enhanced MR imaging with dualphase spiral CT. Korean J Radiol 2003;4:1-8.
54. Kang BK, Lim JH, Kim SH, et al: Preoperative depiction of hepatocellular carcinoma: ferumoxides-enhanced MR imaging versus triple-phase helical CT. Radiology 2003;226:79-85.
55. Kim SH, Choi D, Lim JH, et al: Ferucarbotran-enhanced MRI versus triple-phase MDCT for the preoperative detection of hepatocellular carcinoma. AJR Am J Roentgenol 2005;184:1069-1076.
56. Kim YK, Kwak HS, Kim CS, Chung GH, Han YM, Lee JM: Hepatocellular carcinoma in patients with chronic liver disease: comparison of SPIO-enhanced MR imaging and 16-detector row CT. Radiology 2006;238:531-541.
57. Kim SJ, Kim SH, Lee J, et al: Ferucarbotran-enhanced 3.0-T magnetic resonance imaging using parallel imaging technique compared with triple-phase multidetector row computed tomography for the preoperative detection of hepatocellular carcinoma. J Comput Assist Tomogr 2008;32:379-385.
58. Chang JM, Lee JM, Lee MW, et al: Superparamagnetic iron oxide-enhanced liver magnetic resonance imaging: comparison of 1.5 T and 3.0 T imaging for detection of focal malignant liver lesions. Invest Radiol 2006;41:168-174.
59. Kim MJ, Kim JH, Chung JJ, Park MS, Lim JS, Oh YT: Focal hepatic lesions:detection and characterization with combination gadolinium-and superparamagnetic iron oxide-enhanced MR imaging. Radiology 2003;228:719-726.
60. Tang Y, Yamashita Y, Arakawa A, et al: Detection of hepatocellular carcinoma arising in cirrhotic livers: comparison of gadolinium-and ferumoxides-enhanced MR imaging. AJR Am J Roentgenol 1999;172:1547-1554.
61. Pauleit D, Textor J, Bachmann R, et al: Hepatocellular carcinoma: detection with gadolinium- and ferumoxides-enhanced MR imaging of the liver. Radiology 2002;222:73-80.
62. Ward J, Guthrie JA, Scott DJ, et al: Hepatocellular carcinoma in the cirrhotic liver: double-contrast MR imaging for diagnosis. Radiology 2000;216:154-162.
63. Bhartia B, Ward J, Guthrie JA, Robinson PJ: Hepatocellular carcinoma in cirrhotic livers: double-contrast thin-section MR imaging with pathologic correlation of explanted tissue. AJR Am J Roentgenol 2003;180:577-584.
64. Kim YK, Kwak HS, Han YM, Kim CS: Usefulness of combining sequentially acquired gadobenate dimeglumine-enhanced magnetic resonance imaging and resovist-enhanced magnetic resonance imaging for the detection of hepatocellular carcinoma: comparison with computed tomography hepatic arteriography and computed tomography arterioportography using 16-slice multidetector computed tomography. J Comput Assist Tomogr 2007;31:702-711.
65. Imai Y, Murakami T, Yoshida S, et al: Superparamagnetic iron oxide-enhanced magnetic resonance images of hepatocellular carcinoma: correlation with histological grading. Hepatology 2000;32:205-212.
66. Lim JH, Choi D, Cho SK, et al: Conspicuity of hepatocellular nodular lesions in cirrhotic livers at ferumoxides-enhanced MR imaging: importance of Kupffer cell number. Radiology 2001;220:669-676.
67. Kato H, Kanematsu M, Kondo H, et al: Ferumoxide-enhanced MR imaging of hepatocellular carcinoma: correlation with histologic tumor grade and tumor vascularity. J Magn Reson Imaging 2004;19:76-81.
68. Tanimoto A, Yuasa Y, Shinmoto H, et al: Superparamagnetic iron oxide-mediated hepatic signal intensity change in patients with and without cirrhosis: pulse sequence effects and Kupffer cell function. Radiology 2002;222:661-666.
69. Elizondo G, Weissleder R, Stark DD, et al: Hepatic cirrhosis and hepatitis: MR imaging enhanced with superparamagnetic iron oxide. Radiology 1990;174:797-801.
70. Saito K, Shindo H, Ozuki T, et al: Perfusion study of hypervascular hepatocellular carcinoma with SPIO. Magn Reson Med Sci 2005;4:151-158.
71. Hori M, Murakami T, Kim T, et al: Hemodynamic characterization of focal hepatic lesions: role of ferucarbotran-enhanced dynamic MR imaging using T2-weighted multishot spin-echo echo-planar sequence. J Magn Reson Imaging 2006;23:509-519.
72. Lutz AM, Willmann JK, Goepfert K, Marincek B, Weishaupt D: Hepatocellular carcinoma in cirrhosis: enhancement patterns at dynamic gadolinium- and superparamagnetic iron oxide-enhanced T1-weighted MR imaging. Radiology 2005;237:520-528.
73. Reimer P, Schneider G, Schima W: Hepatobiliary contrast agents for contrast-enhanced MRI of the liver: properties, clinical development and applications. Eur Radiol 2004;14:559-578.
74. Bartolozzi C, Crocetti L, Lencioni R, Cioni D, Della Pina C, Campani D: Biliary and reticuloendothelial impairment in hepatocarcinogenesis: the diagnostic role of tissue-specific MR contrast media. Eur Radiol 2007;17:2519-2530.
75. Rofsky NM, Weinreb JC, Bernardino ME, Young SW, Lee JK, Noz ME: Hepatocellular tumors: characterization with Mn-DPDP-enhanced MR imaging. Radiology 1993;188:53-59.
76. Liou J, Lee JK, Borrello JA, Brown JJ: Differentiation of hepatomas from nonhepatomatous masses: use of MnDPDP-enhanced MR images. Magn Reson Imaging 1994;12:71-79.
77. Helmberger TK, Laubenberger J, Rummeny E, et al: MRI characteristics in focal hepatic disease before and after administration of MnDPDP: discriminant analysis as a diagnostic tool. Eur Radiol 2002;12:62-70.
78. Ba-Ssalamah A, Schima W, Schmook MT, et al: Atypical focal nodular hyperplasia of the liver: imaging features of nonspecific and liver-specific MR contrast agents. AJR Am J Roentgenol 2002;179:1447-1456.
79. Oudkerk M, Torres CG, Song B, et al: Characterization of liver lesions with mangafodipir trisodium-enhanced MR imaging: multicenter study comparing MR and dualphase spiral CT. Radiology 2002;223:517-524.
80. Mathieu D, Coffin C, Kobeiter H, et al: Unexpected MR-T1 enhancement of endocrine liver metastases with mangafodipir. J Magn Reson Imaging 1999;10:193-195.
81. Braga HJ, Choti MA, Lee VS, Paulson EK, Siegelman ES, Bluemke DA: Liver lesions: manganese-enhanced MR and dual-phase helical CT for preoperative detection and characterization comparison with receiver operating characteristic analysis. Radiology 2002;223:525-531.
82. Bartolozzi C, Donati F, Cioni D, Crocetti L, Lencioni R: MnDPDP-enhanced MRI vs dual-phase spiral CT in the detection of hepatocellular carcinoma in cirrhosis. Eur Radiol 2000;10:1697-1702.
83. Ni Y, Marchal G, Zhang X, et al:The uptake of manganese dipyridoxal-diphosphate by chemically induced hepatocellular carcinoma in rats. A correlation between contrast-media-enhanced magnetic resonance imaging, tumor differentiation, and vascularization. Invest Radiol 1993;28:520-528.
84. Murakami T, Baron RL, Peterson MS, et al: Hepatocellular carcinoma: MR imaging with mangafodipir trisodium (Mn-DPDP). Radiology 1996;200:69-77.
85. Scharitzer M, Schima W, Schober E, et al: Characterization of hepatocellular tumors: value of mangafodipir-enhanced magnetic resonance imaging. J Comput Assist Tomogr 2005;29:181-190.
86. Coffin CM, Diche T, Mahfouz A, et al: Benign and malignant hepatocellular tumors: evaluation of tumoral enhancement after mangafodipir trisodium injection on MR imaging. Eur Radiol 1999;9:444-449.
87. Kim JH, Kim MJ, Park YN, et al: Mangafodipir trisodium-enhanced MRI of hepatocellular carcinoma: correlation with histological characteristics. Clin Radiol 2008;63:1195-1204.
88. Kettritz U, Schlund JF, Wilbur K, Eisenberg LB, Semelka RC: Comparison of gadolinium chelates with manganese-DPDP for liver lesion detection and characterization: preliminary results. Magn Reson Imaging 1996;14:1185-1190.
89. Kim SK, Kim SH, Lee WJ, et al: Preoperative detection of hepatocellular carcinoma: ferumoxides-enhanced versus mangafodipir trisodium-enhanced MR imaging. AJR Am J Roentgenol 2002;179:741-750.
90. Youk JH, Lee JM, Kim CS: MRI for detection of hepatocellular carcinoma: comparison of mangafodipir trisodium and gadopentetate dimeglumine contrast agents. AJR Am J Roentgenol 2004;183:1049-1054.
91. Cavagna FM, Maggioni F, Castelli PM, et al: Gadolinium chelates with weak binding to serum proteins. A new class of high-efficiency, general purpose contrast agents for magnetic resonance imaging. Invest Radiol 1997;32:780-796.
92. Volk M, Strotzer M, Lenhart M, et al: Renal time-resolved MR angiography: quantitative comparison of gadobenate dimeglumine and gadopentetate dimeglumine with different doses. Radiology 2001;220:484-488.
93. Pintaske J, Martirosian P, Graf H, et al: Relaxivity of gadopentetate dimeglumine (Magnevist), gadobutrol (Gadovist), and gadobenate dimeglumine (MultiHance) in human blood plasma at 0.2, 1.5, and 3 Tesla. Invest Radiol 2006;41:213-221.
94. Kuwatsuru R, Kadoya M, Ohtomo K, et al: Comparison of gadobenate dimeglumine with gadopentetate dimeglumine for magnetic resonance imaging of liver tumors. Invest Radiol 2001;36:632-641.
95. Schneider G, Maas R, Schultze Kool L, et al: Low-dose gadobenate dimeglumine versus standard dose gadopentetate dimeglumine for contrast-enhanced magnetic resonance imaging of the liver: an intra-individual crossover comparison. Invest Radiol 2003;38:85-94.
96. Petersein J, Spinazzi A, Giovagnoni A, et al: Focal liver lesions: evaluation of the efficacy of gadobenate dimeglumine in MR imaging - a multicenter phase III clinical study. Radiology 2000;215:727-736.
97. Pirovano G, Vanzulli A, Marti-Bonmati L, et al: Evaluation of the accuracy of gadobenate dimeglumine-enhanced MR imaging in the detection and characterization of focal liver lesions. AJR Am J Roentgenol 2000;175:1111-1120.
98. Morana G, Grazioli L, Schneider G, et al: Hypervascular hepatic lesions: dynamic and late enhancement pattern with Gd-BOPTA. Acad Radiol 2002;9(suppl 2):S476-S479.
99. Manfredi R, Maresca G, Baron RL, et al: Delayed MR imaging of hepatocellular carcinoma enhanced by gadobenate dimeglumine (Gd-BOPTA). J Magn Reson Imaging 1999;9:704-710.
100. Grazioli L, Morana G, Caudana R, et al: Hepatocellular carcinoma: correlation between gadobenate dimeglumine-enhanced MRI and pathologic findings. Invest Radiol 2000;35:25-34.
101. Kim HS, Kim MJ, Park MS, Lim JS: Potential conditions causing impairment of selective hepatobiliary enhancement of gadobenate-enhanced delayed MR imaging;in RSNA 2007, Chicago, 2007, pp 484-485.
102. Vogl TJ, Stupavsky A, Pegios W, et al: Hepatocellular carcinoma: evaluation with dynamic and static gadobenate dimeglumine-enhanced MR imaging and histopathologic correlation. Radiology 1997;205:721-728.
103. Kim YK, Kim CS, Kwak HS, Lee JM: Three-dimensional dynamic liver MR imaging using sensitivity encoding for detection of hepatocellular carcinomas: comparison with superparamagnetic iron oxide-enhanced MR imaging. J Magn Reson Imaging 2004;20:826-837.
104. Kim YK, Kim CS, Lee YH, Kwak HS, Lee JM: Comparison of superparamagnetic iron oxide-enhanced and gadobenate dimeglumine-enhanced dynamic MRI for detection of small hepatocellular carcinomas. AJR Am J Roentgenol 2004;182:1217-1223.
105. Kim YK, Kim CS, Chung GH, et al: Comparison of gadobenate dimeglumine-enhanced dynamic MRI and 16-MDCT for the detection of hepatocellular carcinoma. AJR Am J Roentgenol 2006;186:149-157.
106. Choi SH, Lee JM, Yu NC, et al: Hepatocellular carcinoma in liver transplantation candidates: detection with gadobenate dimeglumine-enhanced MRI. AJR Am J Roentgenol 2008;191:529-536.
107. Kim YK, Lee JM, Kim CS, Chung GH, Kim CY, Kim IH: Detection of liver metastases: gadobenate dimeglumine-enhanced three-dimensional dynamic phases and one-hour delayed phase MR imaging versus superparamagnetic iron oxide-enhanced MR imaging. Eur Radiol 2005;15:220-228.
108. Kim YK, Lee JM, Kim CS: Gadobenate dimeglumine-enhanced liver MR imaging: value of dynamic and delayed imaging for the characterization and detection of focal liver lesions. Eur Radiol 2004;14:5-13.
109. Caudana R, Morana G, Pirovano GP, et al: Focal malignant hepatic lesions: MR imaging enhanced with gadolinium benzyloxypropionictetra-acetate (BOPTA) - preliminary results of phase II clinical application. Radiology 1996;199:513-520.
110. Kim JI, Lee JM, Choi JY, et al: The value of gadobenate dimeglumine-enhanced delayed phase MR imaging for characterization of hepatocellular nodules in the cirrhotic liver. Invest Radiol 2008;43:202-210.
111. Park S, Kim MJ, Lim J, et al: Efficacy of gadobenate dimeglumine (Gd-BOPTA)-enhanced hepatobiliary phase MR imaging for the diagnosis of hepatocellular carcinomas; in RSNA 2008, Chicago, 2008.
112. Hamm B, Staks T, Muhler A, et al: Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetics, and MR imaging. Radiology 1995;195:785-792.
113. Reimer P, Rummeny EJ, Shamsi K, et al: Phase II clinical evaluation of Gd-EOBDTPA: dose, safety aspects, and pulse sequence. Radiology 1996;199:177-183.
114. Vogl TJ, Kummel S, Hammerstingl R, et al: Liver tumors: comparison of MR imaging with Gd-EOB-DTPA and Gd-DTPA. Radiology 1996;200:59-67.
115. Huppertz A, Balzer T, Blakeborough A, et al: Improved detection of focal liver lesions at MR imaging: multicenter comparison of gadoxetic acid-enhanced MR images with intraoperative findings. Radiology 2004;230:266-275.
116. Bluemke DA, Sahani D, Amendola M, et al: Efficacy and safety of MR imaging with liver-specific contrast agent: U.S. multicenter phase III study. Radiology 2005;237:89-98.
117. Huppertz A, Haraida S, Kraus A, et al: Enhancement of focal liver lesions at gadoxetic acid-enhanced MR imaging: correlation with histopathologic findings and spiral CT - initial observations. Radiology 2005;234:468-478.
118. Halavaara J, Breuer J, Ayuso C, et al: Liver tumor characterization: comparison between liver-specific gadoxetic acid disodium-enhanced MRI and biphasic CT - a multicenter trial. J Comput Assist Tomogr 2006;30:345-354.
119. Hammerstingl R, Huppertz A, Breuer J, et al: Diagnostic efficacy of gadoxetic acid (Primovist)-enhanced MRI and spiral CT for a therapeutic strategy: comparison with intraoperative and histopathologic findings in focal liver lesions. Eur Radiol 2008;18:457-467.
120. Ni Y, Marchal G, Yu J, Muhler A, Lukito G, Baert AL: Prolonged positive contrast enhancement with Gd-EOB-DTPA in experimental liver tumors: potential value in tissue characterization. J Magn Reson Imaging 1994;4:355-363.
121. Fujita M, Yamamoto R, Fritz-Zieroth B, et al: Contrast enhancement with Gd-EOBDTPA in MR imaging of hepatocellular carcinoma in mice: a comparison with superparamagnetic iron oxide. J Magn Reson Imaging 1996;6:472-477.
122. Fujita M, Yamamoto R, Takahashi M, et al: Paradoxic uptake of Gd-EOB-DTPA by hepatocellular carcinoma in mice: quantitative image analysis. J Magn Reson Imaging 1997;7:768-770.
123. Tsuda N, Kato N, Murayama C, Narazaki M, Yokawa T: Potential for differential diagnosis with gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging in experimental hepatic tumors. Invest Radiol 2004;39:80-88.
124. Tanimoto A, Satoh Y, Yuasa Y, Jinzaki M, Hiramatsu K: Performance of Gd-EOBDTPA and superparamagnetic iron oxide particles in the detection of primary liver cancer: a comparative study by alternative free-response receiver operating characteristic analysis. J Magn Reson Imaging 1997;7:120-124.
125. Saito K, Kotake F, Ito N, et al: Gd-EOBDTPA enhanced MRI for hepatocellular carcinoma: quantitative evaluation of tumor enhancement in hepatobiliary phase. Magn Reson Med Sci 2005;4:1-9.
126. Jung G, Breuer J, Poll LW, et al: Imaging characteristics of hepatocellular carcinoma using the hepatobiliary contrast agent Gd-EOB-DTPA. Acta Radiol 2006;47:15-23.